検索に戻る
案件記録

INJECTABLE HYDROGELS FOR CONTROLLED RELEASE OF IMMUNOMODULATORY COMPOUNDS

発明審査中
2閲覧数
20請求項 · 2 独立
§ Ⅰ

案件概要

発明者

Gillie A. Roth; Eric Andrew Appel; Mark Davis; Emily C. Gale; Santiago Correa

IPC分類

A61K 47/69A61K 9/6A61K 39/A61K 39/15A61K 39/145A61K 39/21A61K 39/39A61P 31/16A61P 35/

CPC分類

A61K47/6937A61K9/6A61K39/15A61K39/145A61K39/21A61K39/39A61P31/16A61P35/A61K2039/54A61K2039/55577A61K2039/55588A61K2039/6093

An immunomodulatory delivery system includes a hydrogel, a first immunomodulatory cargo encapsulated in the cargo, and a second immunomodulatory cargo encapsulated in the hydrogel. The hydrogel includes a polymer non-covalently crossed-linked with a plurality of nanoparticles. The first immunomodulatory cargo is smaller than the second immunomodulatory cargo. A ratio of a diffusivity of the first immunomodulatory cargo through the hydrogel to a diffusivity of the second immunomodulatory cargo through the hydrogel is less than 3.

原文(中国語)

An immunomodulatory delivery system includes a hydrogel, a first immunomodulatory cargo encapsulated in the cargo, and a second immunomodulatory cargo encapsulated in the hydrogel. The hydrogel includes a polymer non-covalently crossed-linked with a plurality of nanoparticles. The first immunomodulatory cargo is smaller than the second immunomodulatory cargo. A ratio of a diffusivity of the first immunomodulatory cargo through the hydrogel to a diffusivity of the second immunomodulatory cargo through the hydrogel is less than 3.

外部リソース